Detecting and Treating Primary Aldosteronism

Abstract

Primary aldosteronism (PA) is the most common cause of mineralocorticoid hypertension. Different studies, using the plasma aldosterone concentration to plasma renin activity ratio (PAC/PRA) for the screening of patients with hypertension, have shown a marked increase in the detection rate of PA. Idiopathic bilateral adrenal hyperplasia (IHA) and aldosterone-producing adrenal adenoma (APA), are the leading causes of primary aldosteronism. Glucocorticoid-remediable aldosteronism (GRA), also called familial hyperaldosteronism type I, familial hyperaldosteronism type II and carcinomas are rare causes of PA. Patients with hypertension and hypokalemia, those with a family history of hypertension and stroke at an early age, or patients with medication-resistant hypertension should be screened for PA using the PAC/PRA ratio. If a high ratio is found, a sodium loading test or a captopril test is warranted to confirm the diagnosis. Adrenal gland imaging is important in subtype differentiation (APA vs IHA). Adrenal venous sampling should be used when other tests prove inconclusive. Genetic testing has facilitated detection of GRA. Surgery is considered the treatment of choice for patients with APA, while bilateral hyperplasia subtypes are treated medically. Normalization of aldosterone levels or aldosterone receptor blockade are necessary to prevent the morbidity and mortality associated with hypertension, hypokalemia, and cardiovascular damage.

diagnosis - treatment - primary aldosteronism

References

• 1 Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism.  Hypertension. 2001;  37 1440-1443
• 2 Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential ant-androgenic activity by a mouse kidney cytosol receptor assay.  Clin Endocrinol (Oxf). 1985;  23 341-347
• 3 Carpenè G, Rocco G, Opocher G, Mantero F. Acute and chronic effect of nifedipine in primary aldosteronism.  Clin Exper Hyper-Theory and practice. 1989;  11 1263-1272
• 4 Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. a detectable cause of curable “essential” hypertension.  JAMA. 1965;  193 200-206
• 5 Conn JW. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954.  J Lab Clin Med. 1990;  116 253-267
• 6 Dupont A. Disappearence of spironolactone-induced gynecomastia during treatment with potassium canrenoate.  Lancet. 1985;  2 731-734
• 7 Epstein M, Menard J, Alexander JC, Roniker B. Eplerenone, a novel and selective aldosterone receptor antagonist: efficacy in patients with mild to moderate hypertension.  Circulation. 2000;  98 S198-S199
• 8 Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas.  Ann Intern Med. 1999;  131 105-108
• 9 Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol.  J Hypertens. 2006;  24 (4) 737-745
• 10 Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension.  Clin Exp Pharmacol. 1994;  21 315-318
• 11 Griffin GT, Melby JC. The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate in idiopathic hyperaldosteronism.  J Clin Hypertens. 1985;  1 265-276
• 12 Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone producing adenoma by measuring plasma renin activity. Results in hypertensive patients.  Arch Intern Med. 1981;  141 1589-1593
• 13 Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism.  Hypertension. 1984;  6 717-723
• 14 Ignatowska-Switalska H, Chodakowska J, Januszewicz W, Feltynowski T, Adamczyk M, Lewondowski J. Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism.  J Hum Hypertens. 1997;  11 373-378
• 15 Jackson RV, Lafferty A, Torpy DJ, Stratakis C. New genetic insights in familial hyperaldosteronism.  Ann N Y Acad Sci. 2002;  970 77-88
• 16 Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism.  J Clin Endocrinol Metab. 1997;  82 3570-3573
• 17 McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism.  Arq Bras Endocrinol Metabol. 2004;  48 682-686
• 18 Mantero F, Fallo F, Opocher G, Armanin D, Boscaro M, Scaroni C. Effect of angiotensin II and converting-enzyme inhibitor (captopril) on blood pressure, PRA and aldosterone in primary aldosteronism.  Clin Sci (Lond). 1981;  61 S289-S293
• 19 Mantero F, Opocher G, Rocco S, Carpenè G, Armanini D. Long-term treatment of mineralocorticoid excess syndromes.  Steroids. 1995;  60 81-86
• 20 Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.  Clin Endocrinol Metab. 2000;  85 637-644
• 21 Mulatero P, Rabbia F, Milan A, Paglieri C, Morellow F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.  Hypertension. 2002;  40 897-902
• 22 Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling.  Metabolism. 2002;  51 350-355
• 23 Pagny JY, Chatellier G, Raynaud A, Plouin PF, Corvol P. Localization of primary hyperaldosteronism.  Ann Endocrinol (Paris). 1988;  49 340-343
• 24 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.  N Engl J Med. 1999;  341 709-717
• 25 Pitt B, Remme W, Faiez Z, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.  N Engl J Med. 2003;  348 1309-1321
• 26 Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart.  Am J Physiol. 2002;  283 H1802-H1810
• 27 Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.  Hypertension. 1998;  31 451-458
• 28 Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives.  Am J Hypertension. 2002;  15 896-902
• 29 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. PAPY Study Investigator . A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.  J Am Coll Cardiol. 2006;  48 ((11)) 2293-2300 , Epub 2006 Nov 13
• 30 Sawka AN, Young WF, Thmpson GB, Grant CS, Farley DR, Leibson C, van Heerden J. Primary aldosteronism: factors associated with normalization of blood pressure after surgery.  Ann Intern Med. 2001;  135 258-261
• 31 Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and rennin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.  Clin Endocrinol (Oxf). 2002;  57 (4) 457-465
• 32 Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.  Eur J Endocrinol. 2004;  150 329-337
• 33 Stokes GS, Monaghan JC, Ryan M, Woodward M. Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.  J Hypertens. 2001;  19 1161-1165
• 34 Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress.  Am J Pathol. 2002;  161 1773-1781
• 35 Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism.  Exp Clin Endocrinol Diabetes. 2002;  110 (2) 80-85
• 36 Young WF, Stanson AW, Grant CSm Thompson GB, van Heerden JA. Primary aldosteronism: adrenal venous sampling.  Surgery. 1996;  120 913-920
• 37 Young Jr WF. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment.  Endocrinology. 2003;  144 2208-2213

Correspondence